首页> 外文会议>IFAC World Congress >Adaptive Control of Bivalirudin in the Cardiac Intensive Care Unit
【24h】

Adaptive Control of Bivalirudin in the Cardiac Intensive Care Unit

机译:心脏重症监护单元中双伐鲁替素的自适应控制

获取原文
获取外文期刊封面目录资料

摘要

Bivalirudin is a direct thrombin inhibitor used in the cardiac intensive care unit in patients who develop an allergic reaction to heparin. Since it is not a commonly used drug, clinical experience with its dosing is sparse. In earlier work (Zhao et al. [2014]) we developed a dynamic system model that accurately predicts the effect of bivalirudin when given dosage over time and patient physiological characteristics. This paper develops adaptive dosage controllers that regulate its effect to desired levels. To that end, and in the case that bivalirudin model parameters are available, we develop a Model Reference Control law. In the case that model parameters are unknown, an indirect Model Reference Adaptive Control scheme is applied to estimate model parameters first and then adapt the controller. Our algorithms are validated using actual data from a large hospital in the Boston area.
机译:Bivalirudin是一种在对肝素过敏反应的患者中使用的心脏重症监护病例中使用的直接凝血酶抑制剂。由于它不是一个常用的药物,临床经验与其给药稀疏。在早期的工作(Zhao等人。[2014])我们开发了一种动态系统模型,可准确预测双valirudin在给予剂量随时间和患者生理特性时的影响。本文开发了适应性剂量控制器,使其对所需水平调节其效果。为此,在可以使用Bivalirudin模型参数的情况下,我们开发了模型参考控制法。在模型参数未知的情况下,将间接模型参考自适应控制方案应用于首先估计模型参数,然后调整控制器。我们的算法使用波士顿地区的大型医院的实际数据进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号